作为一种抗瘤药物的Palbociclib:杀人的许可证
Agnieszka Łupicka-Słowik1, Federica Cossu2, Marcin Sieńczyk1
1Division of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroclaw, Poland.
Molecules (Basel, Switzerland)
|November 27, 2024
概括
作为CDK4/6抑制剂的Palbociclib在治疗激素依赖性乳腺癌和其他恶性瘤方面表现出有前途的表现,通过阻止不受控制的细胞分裂. 研究探讨了它的疗效,耐药机制,以及像PROTACs这样的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 新生细胞的增殖是由细胞周期失调驱动的.
- 循环素依赖性激酶4和6 (CDK4/6) 调节G1到S相过渡.
- CDK4/6抑制剂提供了一个向的抗癌治疗方法.
研究的目的:
- 审查palbociclib的临床试验结果,这是FDA批准的CDK4/6抑制剂.
- 讨论palbociclib在各种癌症中的治疗应用.
- 分析耐药机制,探索新的治疗策略.
主要方法:
- 临床试验数据审查.
- 分析乳腺癌,固体瘤和造血性恶性瘤的治疗应用.
- 研究获得的耐药性和新兴的治疗方式 (例如,PROTACs).
主要成果:
- 帕尔博西克利布 (Palbociclib) 是一种有效的第一类药物,用于治疗荷尔蒙依赖乳腺癌.
- 它在各种恶性瘤中显示出治疗潜力.
- 对palbociclib的耐药性可能会发展,需要进一步的研究.
结论:
- 抑制CDK4/6代表了癌症治疗的重大进展.
- 帕尔博西克利布的疗效已经确立,但耐药性需要持续调查.
- 包括PROTACs在内的下一代疗法有望克服耐药性并扩大治疗选择.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


